Humoral response after SARS-CoV-2 mRNA vaccination in patients with prostate cancer using steroids

Yoneyama, T.; Tanaka, Ryuma; Narita, Takuma; Fujita, Naoki; Okamoto, Teppei; Yamamoto, Hayato; Yoneyama, Takahiro; Hashimoto, Yasuhiro; Οhyama, Chikara

doi:10.1016/j.urolonc.2022.07.015

Cited by 4 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is worth noting that periplocin ( 5 ) demonstrated promising cytotoxic activity against the four human cancer cell lines with all the IC 50 values less than 0.1 μM compared to that of the positive control cisplatin (IC 50 = 7.0 ± 0.3 μM). Both perlplogemn ( 4 ) and periplocin ( 5 ) are known for their cytotoxicity towards different cancer cells, and are now considered as potent leading compounds for several tumors with high drug resistance [ 40 , 41 , 42 ].…”

Section: Resultsmentioning

confidence: 99%

Chemical Constituents of Thesium chinense Turcz and Their In Vitro Antioxidant, Anti-Inflammatory and Cytotoxic Activities

et al. 2023

View full text Add to dashboard Cite

Three novel compounds (1–3) along with twenty-six known compounds, two known steroids (4–5) and twenty-four known phenylpropanoids (6–29) were isolated from the whole plant of Thesium chinense Turcz. The structures of the three new compounds were elucidated on the basis of ESI-MS, HR-ESIMS, 1D and 2D NMR, IR, UV spectroscopic data. The absolute stereochemistry of compound 1 was determined by the Gauge-Including Atomic Orbitals (GIAO) method. The in vitro antioxidant, anti-inflammatory and cytotoxic activities of the isolated compounds were evaluated by DPPH radical-scavenging assay, LPS-activated RAW 264.7 cells model and CCK-8 kit, respectively. Compound 11 showed high antioxidant activity with an SC50 value of 16.2 ± 1.6 μM. Compound 21 showed considerable anti-inflammatory activity with an IC50 value of 28.6 ± 3.0 μM. Compounds 4 and 5 displayed potent cytotoxic activity against human NCI-H292, SiHa, A549, and MKN45 cell lines, with the compound 4 having IC50 values of 17.4 ± 2.4, 22.2 ± 1.1, 9.7 ± 0.9, 9.5 ±0.7 μM, and the compound 5 having all IC50 values less than 0.1 μM in vitro.

show abstract

Section: Resultsmentioning

confidence: 99%

Chemical Constituents of Thesium chinense Turcz and Their In Vitro Antioxidant, Anti-Inflammatory and Cytotoxic Activities

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Other combinations of vaccines including the mRNA variant are being tested with ICIs, including cemiplimab, which is currently approved for skin cancer [ 57 , 58 , 59 , 60 ]. mRNA vaccines are also being combined with androgen receptors and with pembrolizumab [ 61 , 62 , 63 ].…”

Section: Discussionmentioning

confidence: 99%

Immunotherapy for Prostate Cancer: A Current Systematic Review and Patient Centric Perspectives

Rehman¹,

Nisar

Fatima

et al. 2023

JCM

View full text Add to dashboard Cite

Prostate cancer is the most commonly diagnosed cancer in men worldwide, making up 21% of all cancer cases. With 345,000 deaths per year owing to the disease, there is an urgent need to optimize prostate cancer care. This systematic review collated and synthesized findings of completed Phase III clinical trials administering immunotherapy; a current clinical trial index (2022) of all ongoing Phase I–III clinical trial records was also formulated. A total of four Phase III clinical trials with 3588 participants were included administering DCVAC, ipilimumab, personalized peptide vaccine, and the PROSTVAC vaccine. In this original research article, promising results were seen for ipilimumab intervention, with improved overall survival trends. A total of 68 ongoing trial records pooling in 7923 participants were included, spanning completion until June 2028. Immunotherapy is an emerging option for patients with prostate cancer, with immune checkpoint inhibitors and adjuvant therapies forming a large part of the emerging landscape. With various ongoing trials, the characteristics and premises of the prospective findings will be key in improving outcomes in the future.

show abstract

“…Dear Editor, we would like to correspond on the publication “Humoral response after SARS-CoV-2 mRNA vaccination in patients with prostate cancer using steroids [1] .” Ishii et al reported that individuals who used steroids concurrently had considerably poorer humoral responses to the BNT162b2 mRNA vaccination. The presence of CRPC, the accumulation of post-CRPC treatments, and steroid use all had an impact on anti-SARS-CoV-2 S antibody titers [1] . The most recent study provides new data and may suggest the value of the immunization.…”

mentioning

confidence: 99%

SARS-CoV-2 mRNA vaccination, prostate cancer and steroids: Correspondence

Mungmunpuntipantip¹,

Wiwanitkit

2022

Urologic Oncology: Seminars and Original Investigations

View full text Add to dashboard Cite

Humoral response after SARS-CoV-2 mRNA vaccination in patients with prostate cancer using steroids

Cited by 4 publications

References 26 publications

Chemical Constituents of Thesium chinense Turcz and Their In Vitro Antioxidant, Anti-Inflammatory and Cytotoxic Activities

Chemical Constituents of Thesium chinense Turcz and Their In Vitro Antioxidant, Anti-Inflammatory and Cytotoxic Activities

Immunotherapy for Prostate Cancer: A Current Systematic Review and Patient Centric Perspectives

SARS-CoV-2 mRNA vaccination, prostate cancer and steroids: Correspondence

Contact Info

Product

Resources

About